Brief: Bioxyne Says FY25 Revenue Guidance Upgraded To A$28M
12/06/2025 02:50
June 12 (Reuters) - Bioxyne Ltd BXN.AX: FULL YEAR FY2025 REVENUE GUIDANCE UPGRADED FROM A$25M TO A$28M. EXPECTS CONTINUED GROWTH IN ITS AUSTRALIAN OPERATIONS IN FY2026. REVENUE FOR H2 FY2025 IS EXPECTED TO BE A$15.4M Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: Bioxyne Secures A$50M Exclusive German Supply Agreement With Adrex
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal